Table 2 The role of pyroptosis in cancers.
From: Emerging mechanisms of pyroptosis and its therapeutic strategy in cancer
Cancer types | The function of pyroptosis | References |
|---|---|---|
Lung cancer | 1. GSDMD promoted lung cancer development | |
2. P53 interacts with NLPR3 to promote pyroptosis and repress lung cancer development | ||
Liver cancer | 1. DFNA5 inhibit HepG2 cell proliferation | |
2. The NLRP3 inflammasome is downregulated and represses HCC progression | ||
Breast cancer | 1. GSDME and GSDMD repress breast cancer | |
Gastric cancer | 1. GSDMD and GSDME repress the gastric cancer cells proliferation | |
Colorectal cancer | 1. GSDMC promoted colorectal cancer development | |
2. GSDMD inhibit colorectal cancer progression | ||
3. GSDME-mediated pyroptosis of epithelial cells promote the progression of colorectal cancer | ||
Oesophageal squamous cell carcinoma | 1. GSDME represses oesophageal squamous cell carcinoma progression | [85] |
Melanoma cancer | 1. GSDMC are upregulated and promote melanoma cancer progression | |
2. BRAF and MEK inhibitors inhibit melanoma cancer progression via inducing pyroptosis | ||
3. pyroptosis can release HMGB1 and enhance the progression of melanoma | ||
Acute myeloid leukaemia | 1. GSDMD are upregulated and represses leukaemia progression | [90] |
Ovarian cancer | 1. GSDME is downregulated whereas GSDMD and GSDMC are upregulated and repress ovarian cancer progression | |
2. lncRNA GAS5 and lncRNA HOTTIP represses ovarian cancer progression via inducing pyroptosis | ||
Oral squamous cancer | 1. GSDME represses oral squamous cancer progression | [94] |
Glioma | 1. GSDMD represses glioma progression | |
2. Caspase-1-mediated glioma cell pyroptosis inhibit glioma progression |
